SECONDARY ACUTE MYELOID LEUKEMIA - FIRST LINE TREATMENT WITH CYTARABINE, DAUNORUBICIN AND CYCLOSPORINE, A PORTUGUESE HOSPITAL'S EXPERIENCE

被引：0
|
作者：
Nunes, M. [1 ]
Leite, L. [1 ]
Chacim, S. [1 ]
Ferreira, C. [1 ]
Moreira, C. [1 ]
Pereira, D. [1 ]
Brito, M. [1 ]
Marques, M. [1 ]
Viterbo, L. [1 ]
Martins, A. [1 ]
Domingues, N. [1 ]
Moreira, I. [1 ]
Espirito-Santo, A. [1 ]
Oliveira, I. [1 ]
Mariz, J. [1 ]
机构：
[1] Portuguese Oncol Inst, Oncohematol, Porto, Portugal
来源：
HAEMATOLOGICA | 2013年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
B1271
引用
收藏
页码：521 / 522
页数：2
相关论文
共 50 条
  • [1] Cytarabine and daunorubicin for the treatment of acute myeloid leukemia
    Murphy, Tracy
    Yee, Karen W. L.
    EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (16) : 1765 - 1780
  • [2] Population pharmacokinetics of cytarabine, etoposide, and daunorubicin in the treatment for acute myeloid leukemia
    Krogh-Madsen, Mikkel
    Bender, Brendan
    Jensen, Morten Krogh
    Nielsen, Ove Juul
    Friberg, Lena E.
    Honore, Per Hartvig
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (05) : 1155 - 1163
  • [3] Population pharmacokinetics of cytarabine, etoposide, and daunorubicin in the treatment for acute myeloid leukemia
    Mikkel Krogh-Madsen
    Brendan Bender
    Morten Krogh Jensen
    Ove Juul Nielsen
    Lena E. Friberg
    Per Hartvig Honoré
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 1155 - 1163
  • [4] Liposomal cytarabine and daunorubicin (CPX-351) for treatment of acute myeloid leukemia
    Ronson, Aaron
    Tvito, Ariella
    Rowe, Jacob M.
    EXPERT OPINION ON ORPHAN DRUGS, 2017, 5 (04): : 369 - 374
  • [5] Outpatient Administration of Liposomal Daunorubicin and Cytarabine (Vyxeos) in Patients With Secondary Acute Myeloid Leukemia
    Kasner, Margaret T.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (11) : 604 - 606
  • [6] Daunorubicin for the treatment of acute myeloid leukemia
    Bertuzzi, Clara
    Paolini, Stefania
    Visani, Giuseppe
    Piccaluga, Pier Paolo
    EXPERT OPINION ON ORPHAN DRUGS, 2014, 2 (10): : 1075 - 1087
  • [7] The association of topotecan and cytarabine in the treatment of secondary or relapsed acute myeloid leukemia
    Pagano, L
    Mele, L
    Voso, MT
    Chiusolo, P
    Putzulu, R
    Mazzotta, S
    Leone, G
    HAEMATOLOGICA, 2001, 86 (04) : 440 - 441
  • [8] CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
    Lancet, Jeffrey E.
    Uy, Geoffrey L.
    Cortes, Jorge E.
    Newell, Laura F.
    Lin, Tara L.
    Ritchie, Ellen K.
    Stuart, Robert K.
    Strickland, Stephen A.
    Hogge, Donna
    Solomon, Scott R.
    Stone, Richard M.
    Bixby, Dale L.
    Kolitz, Jonathan E.
    Schiller, Gary J.
    Wieduwilt, Matthew J.
    Ryan, Daniel H.
    Hoering, Antje
    Banerjee, Kamalika
    Chiarella, Michael
    Louie, Arthur C.
    Medeiros, Bruno C.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (26) : 2684 - +
  • [9] MITOXANTRONE AND CYTARABINE VERSUS DAUNORUBICIN AND CYTARABINE IN PREVIOUSLY UNTREATED PATIENTS WITH ACUTE MYELOID-LEUKEMIA
    WAHLIN, A
    HORNSTEN, P
    HEDENUS, M
    MALM, C
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1991, 28 (06) : 480 - 483
  • [10] Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML
    Chen, Evan C.
    Fathi, Amir T.
    Brunner, Andrew M.
    ONCOTARGETS AND THERAPY, 2018, 11 : 3425 - 3434
12345